ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2024
Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next generation biopharma company dedicated to ...
Yahoo Finance20d
World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances
TOULOUSE, France & LAKELAND, Mich., February 28, 2025--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a next generation biopharma company dedicated ...
Business Wire28d
ABIONYX Pharma, winner of the France 2030 Plan’s “i-Démo” call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3 rd leading ...
TOULOUSE, France & WESTLAKE, Calif.--(BUSINESS WIRE)--ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of ...
Morningstar1mon
Abionyx Pharma Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Investing26d
Abionyx Pharma SA (ABNX)
TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company ...
Morningstar2d
ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2024
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 ...
Yahoo Finance1mon
ABIONYX Pharma SA (ABNX.PA)
Leverage fair value analysis to evaluate the market value of stocks enabling more informed investment decisions.